Literature DB >> 2370237

The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.

N A Cornick1, G J Cuchural, D R Snydman, N V Jacobus, P Iannini, G Hill, T Cleary, J P O'Keefe, C Pierson, S M Finegold.   

Abstract

A nationwide survey to monitor the susceptibility of the Bacteroides fragilis group, which began in 1981, was continued during 1987. In addition to the eleven drugs evaluated in 1986, sulbactam, a potent beta-lactamase inhibitor, was tested alone and in combination with ampicillin and cefoperazone. Imipenem, ampicillin/sulbactam, cefoperazone/sulbactam, and ticarcillin/clavulanic acid were the most active newer drugs tested, with less than 1% resistance rates. Chloramphenicol, metronidazole and clindamycin also had excellent activity with resistance rates of 0%, 0%, and 3% respectively. Resistance rates to cefoxitin remained stable at 8%. Ceftizoxime and cefotetan had resistance rates of 26% and 29%, respectively. Rates of resistance varied among different institutions and between the various species.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370237     DOI: 10.1093/jac/25.6.1011

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Antibiotic sensitivity of the Bacteroides fragilis group in Europe. European Study Group.

Authors:  I Phillips; A King; C E Nord; B Hoffstedt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

2.  Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.

Authors:  G B Hill
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

Review 3.  Susceptibility testing of anaerobic bacteria: myth, magic, or method?

Authors:  H M Wexler
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

4.  Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S Supran; G J Cuchural; S Finegold; L Harrell; D W Hecht; P Iannini; S Jenkins; C Pierson; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Bacteroides fragilis transfer factor Tn5520: the smallest bacterial mobilizable transposon containing single integrase and mobilization genes that function in Escherichia coli.

Authors:  G Vedantam; T J Novicki; D W Hecht
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

6.  Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content.

Authors:  I Podglajen; J Breuil; I Casin; E Collatz
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

7.  Oligonucleotide probes for detection of cephalosporinases among Bacteroides strains.

Authors:  P Mastrantonio; R Cardines; P Spigaglia
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.

Authors:  I Brook
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Molecular survey of clindamycin and tetracycline resistance determinants in Bacteroides species.

Authors:  H M Fletcher; F L Macrina
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.

Authors:  P Turgeon; V Turgeon; M Gourdeau; J Dubois; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.